Cardiff Oncology
CRDF
19 hedge funds and large institutions have $1.35M invested in Cardiff Oncology in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 8 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
20% more capital invested
Capital invested by funds: $1.12M → $1.35M (+$226K)
1.12% more ownership
Funds ownership: 12.04% → 13.17% (+1.1%)
14% less funds holding
Funds holding: 22 → 19 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$118K |
| 2 |
PFS
Prospera Financial Services
Dallas,
Texas
|
+$30.3K |
| 3 |
Barclays
London,
United Kingdom
|
+$25.2K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$17.6K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARTA
A.R.T. Advisors
New York
|
-$28K |
| 2 |
Morgan Stanley
New York
|
-$14.4K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$10.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7.57K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$4K |
CRDF Hedge Fund Activity: Q4 2019 in Review
19 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2019, worth a combined $1.35M — up 20% from $1.12M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CRDF and 5 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 5 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $118K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $28K sold.
- 19 institutional investors held Cardiff Oncology (CRDF) as of Q4 2019, down from 22 in Q3 2019.
- Funds reported $1.35M of Cardiff Oncology stock for Q4 2019, up 20% quarter-over-quarter.
- 5 funds opened new Cardiff Oncology positions in Q4 2019 and 8 closed out, a net change of -3 holders.
- The largest Cardiff Oncology buyer in Q4 2019 was Armistice Capital, an estimated $118K added.
- The largest Cardiff Oncology seller in Q4 2019 was A.R.T. Advisors, an estimated $28K sold.
Based on aggregated 13F filings for Q4 2019.